Skip to main content
News Latz 12.2019
Investigated the fine-tuning of macrophages: Prof. Dr. Eicke Latz (left) and Mario Lauterbach (right) from the Institute of Innate Immunity at the University of Bonn.
© Rolf Müller/UKB

Publication

Macrophage Metabolism Publication in Immunity

Macrophages have two faces: In healthy tissue, they perform important tasks and support their environment. However during an infection, they stop this work and hunt down the pathogens instead. Upon coming into contact with bacteria they change their metabolism drastically within minutes. This is shown by a new study under the leadership of the University of Bonn, which has now been published in the journal "Immunity". In the medium term, the results may lead to new vaccination strategies, but also to new approaches for combating autoimmune diseases.

The Study was lead by Cluster Member and Speaker Prof. Eicke Latz.


Publication

Mario A. Lauterbach, Jasmin E. Hanke, Magdalini Serefidou, Matthew S. J. Mangan, Carl-Christian Kolbe, Timo Hess, Maximilian Rothe, Romina Kaiser, Florian Hoss, Jan Gehlen, Gudrun Engels, Maike Kreutzenbeck, Susanne V. Schmidt, Anette Christ, Axel Imhof, Karsten Hiller & Eicke Latz: Toll-like receptor signaling rewires macrophage metabolism and promotes histone acetylation via ATP-citrate lyase; Immunity; DOI: 10.1016/j.immuni.2019.11.009

Related news

Prof. Christian Strassburg, Direktor der Klinik für Allgemeine Innere Medizin am UKB, mahnt: „Die Abnehmpille ist nicht einfach nur irgendein Spaßfaktor, um jetzt ein bisschen abzunehmen!“

Publication

Weight-Loss Pill Instead of Injection: Finally, an Easy Way to Lose Weight?

—As of September 1, semaglutide will be available in Germany for the treatment of overweight and obesity in tablet form for the first time. The therapy, previously known primarily as a “weight-loss injection,” can now also be taken orally. The market launch is likely to attract considerable interest – but anyone considering treatment should be aware of one thing first: the tablet is not a way to lose a few kilos, but a prescription medication for the treatment of a chronic disease.
View entry
Prof. Matthias Geyer, - together with Prof. Robert P. Fisher from New York, provides an overview of the current state of research on the transcriptional regulation of cyclin-dependent kinases (CDKs) and the prospects for cancer treatment.

Publication

A Ray of Hope in the Fight Against Cancer

—Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the UKB in collaboration with Prof. Robert P. Fisher and has now been published.
View entry
(from left) Julia Nicke and Dr. Mona Malek Mohammadi have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury.

Publication

Central Hub for Heart Repair Discovered Bonn study: Heart muscle interaction enables cardiac regeneration in the neonatal heart

—Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).
View entry

Back to the news overview